Summary Estraumustine phosphate (EMP), a cytotoxic drug used in the treatment of prostatic carcinoma, has been shown to exert cytotoxic effects on glioma cells in vitro. The drug uptake is assumed to depend on a specific estramustine binding protein (EMBP). One (Kruse et al., 1988b) . The anti-tumouros activity seems, at least partially, to be coupled to the presence of a specific estramustine binding protein (EMBP) in the prostatic tumour cells (Fliichter et al., 1989; Bjork et al., 1985) . By using various techniques including immunohistochemistry and radioimmunoassay, EMBP has also been demonstrated in glioma cells in vitro and in specimens from human brain tumour tissue (von Schoultz et al., 1988; von Schoultz et al., 1991) . It (Gunnarsson et al., 1984) . The given dose is routinely used in prostatic carcinoma patients. All patients received routinely 8 mg betamethason intravenously 12 and 2 h before surgery. Nine patients had been treated with betamethason at most for one week before surgery due to severe cerbral edema. Prophylactic antacid medication consisting of magnesium and aluminium hydroxide was given to five of the patients with earlier dyspepsia or ventricular ulcera. Exclusion criteries for the study included cardiac failure, angina pectoris, and impaired liver and renal function. The study was approved by the local ethics committee and informed consent was obtained individually from all patients.
. The anti-tumouros activity seems, at least partially, to be coupled to the presence of a specific estramustine binding protein (EMBP) in the prostatic tumour cells (Fliichter et al., 1989; Bjork et al., 1985) . By using various techniques including immunohistochemistry and radioimmunoassay, EMBP has also been demonstrated in glioma cells in vitro and in specimens from human brain tumour tissue (von Schoultz et al., 1988; von Schoultz et al., 1991) . It has been suggested that EMBP did take part in the accumulation of the active metabolites estramustine (EaM) and estromustine (EoM) in prostatic carcinoma cells (Bjork et al., 1985; Norlen et al., 1988; Kruse et al., 1988a) and in malignant glioma cells (von Schoultz et al., 1988; von Schoultz et al., 1989 (Gunnarsson et al., 1984) . The given dose is routinely used in prostatic carcinoma patients. All patients received routinely 8 mg betamethason intravenously 12 and 2 h before surgery. Nine patients had been treated with betamethason at most for one week before surgery due to severe cerbral edema. Prophylactic antacid medication consisting of magnesium and aluminium hydroxide was given to five of the patients with earlier dyspepsia or ventricular ulcera. Exclusion criteries for the study included cardiac failure, angina pectoris, and impaired liver and renal function. The study was approved by the local ethics committee and informed consent was obtained individually from all patients.
Surgery
At surgery, specimens of tumour tissue were collected and venous blood samples were taken for analysis of EaM and EoM. The interval between administration of EMP and sample taking was approximately 12-14h. In some patients it was possible to collect cystic fluid from tumour. Specimens for analysis were removed with precaution in order to avoid denaturation. The samples were immediately frozen and stored at -70'C until analysed. Additional tissue samples were also taken for histopathological routine examination and immunohistochemical staining for EMBP.
Analysis of EMP metabolites, EaM and EoM EMP metabolites were measured in tumour specimens, serum, CSF, and cystic fluid, EaM and EoM were analysed using gas chromatography according to a method earlier described (Andersson et al., 1981; Andersson et al., 1982) . The method was further modified for analysing tissue specimens. Tissue samples were homogenised with 15 volumes of methanol. Briefly, the extracts were evaporated and the residues dissolved in 10 ml of water, extracted with hexane and separated on an aluminumoxide column. The samples were dissolved in xylene and quantified by gas chromatography with NP detection (HP 5890, Hewlett Packard).
Immunohistochemistry
The presence of EMBP in the tumour tissue was assessed by the indirect antibody peroxidase technique on paraffin embedded material (Sternberger, 1979; Hsu et al., 1981; von Schoultz et al., 1988) . Endogenous peroxidase activity was blocked by addition of H202 in methanol. A primary mouse monoclonal antibody (Mab EMBP-1) (Kabi-Pharmacia AB, Helsingborg, Sweden) raised against purified rat EMBP was added diluted 1/10 to the sections for 1/2-1 h. The antibody had a demonstrated cross reactivity to human EMBP (Bjork et al., 1985) . It must be emphasised that the doses used in the studies on prostatic carcinoma were at least twice those we used in the present study, i.e. 2 x 560 mg/day or 2 x 840 mg/day (Bjork et al., 1985) or 420 mg as a single dose (Gunnarsson et al., 1984 (Forsgren et al., 1979a,b) and the anti-tumouros effect of EMP has been suggested to be dependent on the presence of this protein (Bjork et al., 1985; Fliichter et al., 1989 (Vallee et al., 1982; Caceres et al., 1984) . This protein is known to have binding affinity for estramustine and its binding has been suggested to inhibit brain microtubule assembly in vitro (Friden et al., 1987; Steams & Tew, 1988) . Thus, it could be a possibility that EMBP and MAP-2 have common antigenic properties which actually could mean that the EMBP immunohistochemically detected could in fact be MAP-2. Future studies will evaluate this.
In conclusion, the present study demonstrates a high uptake and retention of the metabolites of orally administered EMP in human brain tumour 
